docs/_posts/mauro-nievoff/2022-09-26-re_oncology_size_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_biomarker_result_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_granular_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_location_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_temporal_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_test_result_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_wip_en.md
docs/_posts/mauro-nievoff/2022-09-28-redl_oncology_size_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_biomarker_result_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_granular_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_location_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_temporal_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_test_result_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_demographic_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_family_history_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_problem_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_response_to_treatment_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_smoking_status_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_test_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_treatment_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_demographic_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_family_history_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_problem_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_response_to_treatment_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_smoking_status_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_treatment_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_wip_en.md
docs/_posts/mauro-nievoff/2022-11-03-oncology_general_pipeline_en.md
docs/_posts/mauro-nievoff/2022-11-04-oncology_biomarker_pipeline_en.md
docs/_posts/mauro-nievoff/2022-11-04-oncology_diagnosis_pipeline_en.md
docs/_posts/mauro-nievoff/2022-11-04-oncology_therapy_pipeline_en.md
docs/_posts/mauro-nievoff/2022-12-01-oncology_biomarker_pipeline_en.md
docs/_posts/mauro-nievoff/2022-12-01-oncology_diagnosis_pipeline_en.md
docs/_posts/mauro-nievoff/2022-12-01-oncology_general_pipeline_en.md
docs/_posts/mauro-nievoff/2022-12-01-oncology_therapy_pipeline_en.md
docs/_posts/mauro-nievoff/2022-09-26-re_oncology_size_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_biomarker_result_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_granular_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_location_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_temporal_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_test_result_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_wip_en.md
docs/_posts/mauro-nievoff/2022-09-28-redl_oncology_size_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_biomarker_result_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_granular_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_location_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_temporal_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_test_result_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_demographic_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_family_history_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_problem_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_response_to_treatment_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_smoking_status_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_test_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_treatment_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_demographic_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_family_history_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_problem_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_response_to_treatment_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_smoking_status_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_treatment_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_wip_en.md
docs/_posts/mauro-nievoff/2022-11-03-oncology_general_pipeline_en.md
docs/_posts/mauro-nievoff/2022-11-04-oncology_biomarker_pipeline_en.md
docs/_posts/mauro-nievoff/2022-11-04-oncology_diagnosis_pipeline_en.md
docs/_posts/mauro-nievoff/2022-11-04-oncology_therapy_pipeline_en.md
docs/_posts/mauro-nievoff/2022-12-01-oncology_biomarker_pipeline_en.md
docs/_posts/mauro-nievoff/2022-12-01-oncology_diagnosis_pipeline_en.md
docs/_posts/mauro-nievoff/2022-12-01-oncology_general_pipeline_en.md
docs/_posts/mauro-nievoff/2022-12-01-oncology_therapy_pipeline_en.md
